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Associations between chronic pain and poor health have been well established.  Chronic pain has significant detrimental effects on general, psychological and social health (Magni et al., 1993; Becker et al., 1997; Gureje et al., 1998; Breivik et al., 2006) and is associated with increased mortality (Kareholt and Brattberg, 1998; Macfarlane et al., 2001; Smith et al., 2003; McBeth et al., 2009).  A relationship between chronic pain and subsequent cancer has also been suggested, but requires further examination.  

A study by McBeth et al in 2003 found an excess incidence of cancer in those with regional pain and those with widespread pain compared with those reporting no pain (McBeth et al., 2003).  In addition to overall cancers, there was an increased risk of breast, prostate, bowel and lung cancer in those with widespread pain.  Attempts to replicate these findings have not been successful with later studies finding little association.  Smith et al reported no significant association between all chronic pain and subsequent cancer in a cohort of middle-aged women, although they did find a higher risk of cancer among women with chronic pain of the head and abdomen (Smith et al., 2003).  Dreyer et al found no association between confirmed fibromyalgia and cancer in women referred to hospital, but did find an increased risk of all cancers, breast cancer, and lymphatic/haematological cancer in women referred for muscle pain who did not meet the criteria for fibromyalgia (Dreyer et al., 2007).








Study design and participants
A record linkage study between an existing dataset and the routinely collected national cancer registration dataset was undertaken.

Grampian dataset
The Grampian cohort, established in July 1996 (Elliott et al., 1999), consists of 6,940 adults (aged 25 and over) from across the Grampian region of North-east Scotland.  Full details of the sampling methodology and process have been reported previously (Smith et al., 2005).

Data from the cohort were collected by self-completion postal questionnaire. The presence of chronic pain was determined using two questions based on the International Study for the Association of Pain (IASP) definition (IASP, 1986).  Individuals with chronic pain were identified by affirmative answers to two questions: (i) Are you currently troubled by pain or discomfort, either all the time or on and off? (ii) Have you had this pain or discomfort for more than three months?  Respondents answering positively to these two questions were also asked to indicate what caused their pain: “angina”, “arthritis”, “back pain”, “injury”, “cancer”, “don’t know”, and “other” with the “other” cause specified as free text.  Respondents could tick as many causes as they wished.  Further information on the cause of pain i.e. type of injury or type of arthritis was not available.

Chronic pain severity was assessed using the Chronic Pain Grade questionnaire, a seven-item instrument that measures severity in two dimensions: intensity and disability (Von Korff et al., 1992; Smith et al., 1997).  The questionnaire inquires about current pain and pain over the previous 6 months and classifies chronic pain into four hierarchical grades: Grade I (low disability-low intensity), Grade II (low disability-high intensity), Grade III (high disability-moderately limiting) and Grade IV (high disability-severely limiting). 

National cancer registration dataset
In Scotland, routinely collected health information and statistics are collated and stored in a national database by the Information Services Division (ISD) on behalf of NHS Scotland. Linking population-based cohorts with national datasets in Scotland has already been shown to be achievable, reliable and accurate for epidemiological research (West of Scotland Coronary Prevention Study Group, 1995; Ramsay et al., 1999; Nitsch et al., 2006).  Data requested from the national cancer registration dataset included: date of incidence, cancer site, tumour number and tumour type, for any cancers, between 1996 and 2006 inclusive, relevant to the Grampian cohort. 

Record linkage
A copy of the Grampian dataset was forwarded to the Medical Records Linkage Team at ISD who undertook the linkage.  Data were linked through standard procedures based on common patient identifiable fields.  The new dataset was stripped of patient identifiers by ISD and returned to the research team in an anonymised format.  This new dataset allowed detailed analysis of the data, whilst ensuring patient confidentiality.  The study was formally approved by the Privacy Advisory Committee of NHS National Services, Scotland.  Grampian Research Ethics Committee who had approved the original questionnaire study confirmed that ethical approval was not required for this linkage study since no new patient information was being collected and data being analysed were fully anonymised.

Statistical analysis
Data were analysed using SPSS for Windows (version 16).  All cancer codes were converted to a standard format using the International Classification of Diseases 10th revision (ICD 10) (WHO, 1992).  Non-melanoma skin cancers (ICD 10 C44) were excluded from the analysis since the recording of this type of cancer is less complete and less accurate than other cancer types and such cancers are relatively common and usually non-fatal.  In addition to examining all cancers, eight cancer specific sites were examined: Lung, trachea and bronchus (ICD 10 C33-C34), Colorectal (ICD 10 C18-C20), Breast (ICD 10 C50), Prostate (ICD 10 C61), Kidney and bladder (ICD 10 C64-C65), Oesophagus and stomach (ICD 10 C15-C16), Female reproductive (ICD 10 C53, C54, C56), Lymphoma and leukaemia (ICD 10 C81-C96).  All other cancer sites had small numbers which didn’t allow site-specific analyses.  These remaining cancers were therefore grouped together as ‘other cancers’.  For the purposes of the site-specific analyses only the first occurrence of each cancer site was included and data were only censored for cancers of the same type, not previous cancers at a different site.  








Of the 6,940 individuals in the original Grampian cohort, ISD linked 5,853 (84.3%) to their database.  All individuals known to have cancer at baseline were excluded from further analysis.  This included: a) all individuals with a cancer registration in the six months prior to the baseline questionnaire (January 1996 to July 1996) notified to us by ISD (n=25) and b) all individuals attributing the cause of their chronic pain to cancer in the baseline questionnaire (n=50).   A total of 984 cancers occurred in the remaining linked cohort of individuals in the ten years since the baseline study.  After excluding non-melanoma skin cancers and cancers which were not first occurrences for each specified site, a total of 607 people, with 646 cancers, were available for analysis.  

The overall cancer incidence in the cohort was 10.4% over the ten years, with a similar cancer incidence in each year of diagnosis.  This was equivalent to an average annual crude incidence rate of 1037.1 per 100,000 persons.  The most common cancers were lung, trachea and bronchus (2.1%); colorectal (1.5%); breast (1.3%); and prostate (1.2%) (Table 1).  The overall cancer incidence and cancer specific incidences were similar for those with and without chronic pain.     

Unadjusted survival analysis found no significant associations between chronic pain and all cancers and most site-specific cancers (Table 2).  Those with chronic pain were significantly more likely to develop lymphoma/leukaemia than those without chronic pain on unadjusted analysis (HR 4.79, 99% CI 1.02-22.59).  After adjustment for age and sex, the trend remained, but the association was no longer significant (HR 4.33, 99% CI 0.92-20.47).  

Table 3 presents the hazard ratios and 99% confidence intervals for cancer incidence by cause of chronic pain.  There was a consistent elevated effect with lymphoma/leukaemia across all causes of chronic pain, although only the association with chronic pain reportedly caused by arthritis remained significant (HR 5.05, 99% CI 1.01-25.62) after adjustment for sex and age.  We found no other significant associations between the reported cause of chronic pain and cancer incidence (Table 3).  







In this, the largest study to examine chronic pain and subsequent cancer so far, we found little association between chronic pain and cancer incidence over the ten year period of follow-up suggesting that those with chronic pain are not at a significantly increased risk of developing cancer.   We did find an increased risk of lymphoma and leukaemia for all chronic pain and various causes of chronic pain although many of the elevated effects were not significant possibly due to small numbers.  

Our findings are not consistent with those reported by McBeth et al (McBeth at al., 2003).  Differences in the study population or definition of pain used may be partly responsible for the differences, although 83% of those reporting widespread pain in that study also met the IASP definition of chronic pain used in this study.  Our results are more consistent with studies reporting little relationship between chronic pain and cancer ((Smith et al., 2003; Dreyer et al., 2007).  Our finding of a potential increased risk of lymphoma and leukaemia in those reporting chronic pain is also consistent with studies that have shown that those with rheumatoid arthritis have an increased risk of cancer, particularly non-Hodgkin’s lymphoma (Myllykangas-Luosujarvi et al., 1995; Leandro and Isenberg, 2001).
  
This study linked data from a large community dataset with high quality routinely collected NHS data.  The Scottish Cancer Registry is internationally recognised as among the most complete in the world (Scottish Executive Health Department, 2001).    Errors in the coding of cancers in the National dataset are rare and unlikely to have had an impact on our findings.  There can be delays in the recording of cancer events on the National registers.  However, any such delays are likely to have been random across the pain groups and unlikely to have caused bias in our results.  We had a relatively large sample of both men and women and a relatively long follow-up period.  We also had a larger number of registered cancers within our dataset (n=646) than the previous studies (n=395, n=258 and n=55) (McBeth et al., 2003; Smith et al., 2003; Dreyer et al., 2007).  Information from the cohort was collected via a validated questionnaire.  The response rate to the questionnaire was high (82.3%) as was the linkage rate between the two datasets (84.3%).  The statistical analysis allowed adjustment for age and sex and used conservative indicators of statistical significance.  The results are therefore likely to be robust and generaliseable.  The use of a broad definition of chronic pain means that those with less clinically important pain may have been included in the chronic pain group, possibly causing us to underestimate the association.  However, we found no significant differences between those with severe chronic pain compared to mild chronic pain.  Our overall average annual crude incidence rate in the cohort of 1037.1 per 100,000 persons was slightly higher than the Scottish average annual crude incidence rate of 734.8 per 100,000 persons for those aged 25 and over (ISD website, 2009).  This difference may reflect variations in the socio-demographic composition of our cohort compared to the Scottish general population or suggest that respondents to our survey tended to have poorer health.  Finally, we were not able to examine the potential effects of additional unmeasured confounders, such as smoking, on our outcomes, although the study by Macfarlane et al, (Mcfarlane et al., 2001) was robust to adjustment for current smoking status, and found no significant association between chronic widespread pain and smoking prevalence.
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Table 1: Cancer incidence across chronic pain groups

Cancer site	Totaln (%)	No chronic painn (%)	Any chronic painn (%)
All cancers	607 (10.4)	156 (9.1)	451 (10.9)
Lung, trachea & bronchus (ICD 10 C33-C34)	122 (2.1)	32 (1.9)	90 (2.2)
Colorectal (ICD 10 C18-C20)	88 (1.5)	24 (1.4)	64 (1.5)
Breast (ICD 10 C50)	77 (1.3)	27 (1.6)	50 (1.2)
Prostate (ICD 10 C61)	72 (1.2)	16 (0.9)	56 (1.4)
Kidney & Bladder (ICD 10 C64-C65)	54 (0.9)	17 (1.0)	37 (0.9)
Oesophagus & Stomach (ICD 10 C15-C16)	46 (0.8)	12 (0.7)	34 (0.8)
Female reproductive (ICD 10 C53, C54, C56)	37 (0.6)	11 (0.6)	26 (0.6)
Lymphoma & Leukaemia (ICD 10 C81-C96)	37 (0.6)	3 (0.2)	34 (0.8)






Table 2: Survival analysis for cancer incidence and chronic pain (any chronic pain compared against no chronic pain)

Cancer site	Unadjusted hazard ratio (99% confidence interval)	Adjusted hazard ratio(99% confidence interval) *
All cancers	1.22 (0.96-1.54)	1.08 (0.85-1.37)
Lung, trachea & bronchus	1.93 (0.70-2.03)	1.07 (0.63-1.81)
Colorectal 	1.13 (0.61-2.09)	0.95 (0.51-1.77)
Breast 	0.79 (0.43-1.46)	0.74 (0.40-1.38)
Prostate 	1.48 (0.71-3.07)	1.26 (0.61-2.62)
Kidney & bladder 	0.92 (0.43-1.96)	0.83 (0.39-1.78)
Oesophagus & stomach 	1.20 (0.51-2.85)	1.04 (0.44-2.46)
Female reproductive 	1.00 (0.40-2.53)	0.90 (0.36-2.29)
Lymphoma & leukaemia 	4.79 (1.02-22.59)	4.33 (0.92-20.47)
Other cancers 	1.61 (0.86-3.03)	1.41 (0.75-2.65)

* All cancers adjusted for age & sex, except breast, prostate and female reproductive cancers which were adjusted for age only


Table 3: Survival analysis for cancer incidence and cause of chronic pain (figures are adjusted hazard ratio (99% confidence interval)*)

Cancer site	Arthritis(n=1920)	Angina(n=421)	Back pain(n=1379)	Injury(n=479)
All cancers	1.07 (0.82-1.41)	0.93 (0.61-1.41)	1.06 (0.78-1.43)	0.96 (0.62-1.49)
Lung, trachea & bronchus	1.07 (0.59-1.95)	1.15 (0.48-2.75)	1.08 (0.55-2.11)	0.62 (0.20-1.95)
Colorectal 	1.03 (0.52-2.03)	0.80 (0.28-2.32)	1.01 (0.46-2.21)	0.99 (0.33-2.98)
Breast 	0.84 (0.41-1.71)	0.34 (0.07-1.65)	0.76 (0.34-1.69)	0.89 (0.30-2.64)
Prostate 	1.14 (0.50-2.61)	0.86 (0.22-3.32)	1.28 (0.52-3.14)	0.84 (0.20-3.53)
Kidney & Bladder 	0.75 (0.31-1.83)	1.11 (0.36-3.41)	0.75 (0.27-2.11)	0.57 (0.11-2.85)
Oesophagus & Stomach 	1.04 (0.39-2.76)	0.93 (0.23-3.73)	1.27 (0.44-3.63)	1.38 (0.35-5.44)
Female reproductive 	0.99 (0.34-2.86)	0.57 (0.08-4.37)	0.76 (0.22-2.66)	0.91 (0.17-4.89)
Lymphoma & Leukaemia 	5.05 (1.01-25.62)	2.80 (0.31-25.37)	3.99 (0.72-2.41)	5.12 (0.78-33.68)
Other cancers 	1.34 (0.66-2.73)	1.32 (0.47-3.69)	1.06 (0.47-2.41)	1.26 (0.43-3.68)

* All cancers adjusted for age & sex, except breast, prostate and female reproductive cancers which were adjusted for age only


Table 4: Survival analysis for cancer incidence and chronic pain severity (severe compared against mild)

Cancer site	Unadjusted hazard ratio (99% confidence interval)	Adjusted hazard ratio(99% confidence interval) *
All cancers	1.06 (0.81-1.39)	1.00 (0.76-1.32)
Lung, trachea & bronchus	1.75 (0.93-3.20)	1.69 (0.92-3.10)
Colorectal 	1.00 (0.47-2.12)	0.89 (0.42-1.89)
Breast 	0.55 (0.23-1.31)	0.53 (0.22-1.28)
Prostate 	0.88 (0.40-1.95)	0.78 (0.35-1.73)
Kidney & bladder 	0.77 (0.28-2.10)	0.79 (0.29-2.17)
Oesophagus & stomach 	1.04 (0.36-3.02)	0.93 (0.32-2.74)
Female reproductive 	1.19 (0.37-3.78)	1.12 (0.35-3.57)
Lymphoma & leukaemia 	0.77 (0.27-2.22)	0.75 (0.26-2.19)
Other cancers 	1.29 (0.69-2.42)	1.23 (0.65-2.30)

* All cancers adjusted for age & sex, except breast, prostate and female reproductive cancers which were adjusted for age only
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